Answers are grounded in this paper and cite their sources.
Targeting proteins involved in angiogenesis represents a promising strategy in cancer therapy, with vascular endothelial growth factor (VEGF) emerging as a notable candidate. The oncolytic Newcastle disease virus (NDV) has shown potential as a virotherapy agent for cancer. This study aims to investigate the oncolytic potency and mechanism of Indonesian NDV in rat mammary carcinoma models, by examining the expression of Ki67 and VEGF protein. Rats were divided into two groups: control (K0) and virotherapy (K1). The K0 groups received in- tratumoral administrations of 500 μL phosphate-buffered saline, while K1 received 27 HAU per 500 μL of NDV Tabanan-1/ARP/2017 once per day for four consecutive days. On the 15th day following the initiation of therapy, all the rats were euthanized, and tumor tissue was collected. The tissue was then processed histologically and stained with anti-Ki67 and anti-VEGF. Histopathologically, the virotherapy group exhibited fewer blood vessels than the control group. NDV therapy significantly reduced both the Ki67 and VEGF expression. In conclusion, NDV Tabanan-1/ARP/2017 demonstrates potential as a virotherapy agent in rat mammary carcinoma models.
No takes yet. Share an insight, caveat, or question.
Sewoyo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: